SR
Saggar Rajeev
Chief Medical Officer
OFFICERM
€356,563
▼ Sales (11 ops.)
Insider track record
ExecutiveAcross 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Browse the complete record of transactions filed by Saggar Rajeev, Chief Medical Officer. Director active across 1 company, notably Liquidia Corp. In total, 21 filings have been published. Split: 0 buy · 11 sells. Total volume traded: €357k. Activity tracked since 18 July 2022. The latest transaction was disclosed on 21 April 2025 (Cession). Regulator: SEC (Form 4). All data is openly available.
Declarations21 total
3,531 sharesCommon StockSEC:0001104659-26-043265
3,531 sharesCommon StockSEC:0001104659-26-043265:0
3,531 sharesCommon StockSEC:0001104659-26-003361
3,531 sharesCommon StockSEC:0001104659-26-003361:0
3,530 sharesCommon StockSEC:0001104659-25-099750:0
3,530 sharesCommon StockSEC:0001104659-25-099750
2,450 shares@ US$13.678.2% of flowCommon StockSEC:0001104659-25-038008:0
3,714 shares@ US$13.5712.5% of flowCommon StockSEC:0001104659-25-035543:0
2,445 shares@ US$13.008.6% of flowCommon StockSEC:0001104659-25-005669:0
71,780 shares0Common StockSEC:0001104659-25-003475:0
2,526 shares@ US$11.197.3% of flowCommon StockSEC:0001104659-24-110565:0
2,260 shares@ US$11.10776.5% of flowCommon StockSEC:0001104659-24-108768:0
1,873 shares@ US$11.135.4% of flowCommon StockSEC:0001104659-24-081516:0
1,470 shares@ US$12.534.8% of flowCommon StockSEC:0001104659-24-079924:0
1,649 shares@ US$13.685.9% of flowCommon StockSEC:0001104659-24-050664:0
1,525 shares@ US$14.585.8% of flowCommon StockSEC:0001104659-24-047891:0
1,654 shares@ US$15.826.7% of flowCommon StockSEC:0001104659-24-036346:0
56,492 shares0Common StockSEC:0001104659-24-004155:0
14,887 shares@ US$7.4228.4% of flowCommon StockSEC:0001104659-23-127037:0
83,333 shares0Common StockSEC:0001104659-23-003883:0
93,834 shares0Common StockSEC:0001104659-22-081182:0
About Saggar Rajeev
Rajeev Saggar is the Chief Medical Officer of Liquidia Corp. In this role, he oversees the medical and clinical activities of the company, ensuring that products meet safety and efficacy standards. His expertise is essential for the development of innovative therapeutic solutions.